Skip to main content
Download PDF

Disulfiram attenuates hypoxia-induced pulmonary hypertension by inhibiting GSDMD cleavage and pyroptosis in HPASMCs

Respiratory Research volume 23, Article number: 353 (2022) Cite this article

Abstract

Background

Pulmonary hypertension (PH) is characterized by progressive pulmonary arterial remodelling, associated with different severities of inflammation and altered immune processes. Disulfiram eliminates the formation of N-gasdermin D (GSDMD) plasma membrane pores to prevent pyroptosis. Pyroptosis is a form of lytic cell death characterized by inflammasome activation and proinflammatory cytokine release that acts in the development of PH. We sought to investigate whether disulfiram could alleviate hypoxia-induced PH by inhibiting pyroptosis.

Methods

To investigate whether disulfiram alleviates the progression of pulmonary hypertension, rodents were exposed to chronic hypoxia (10% oxygen, 4 weeks) to induce PH. The severity of PH was assessed by measuring right ventricular systolic pressure, mean pulmonary artery pressure, and the degree of right ventricular hypertrophy. Western blotting was used to measure proteins associated with the pyroptosis pathway, and ELISA was performed to measure the secretion of IL-18 and IL-1β, both of which are the primary methods for assessing pyroptosis.

Results

IL-18 and IL-1β concentrations were higher in patients with PH than in normal controls. Disulfiram suppressed the progression of PH in mice and rats through the alleviation of pulmonary arterial remodelling. Pyroptosis-related proteins and the inflammasome were activated in rodent models of PH. Disulfiram inhibited the processing of GSDMD into N-GSDMD and attenuated the secretion of IL-1β and IL18. In vivo experiments showed that disulfiram also inhibited lytic death in HPASMCs.

Conclusions

Disulfiram treatment reduces PH progression through suppressing vascular remodelling by inhibiting GSDMD cleavage and pyroptosis. It might become a novel therapeutic option for the treatment of PH.

Background

Pulmonary hypertension (PH) is a class of haemdynamic disturbances characterized by progressive pulmonary arterial remodelling, vasoconstriction and thrombosis associated with different severities of inflammation and altered immune processes, ultimately leading to right heart failure and death [1]. Hypertrophy and proliferation of human pulmonary artery smooth muscle cells (HPASMCs) are considered important pathophysiological changes of pulmonary arterial remodelling in PH [2]. Although inflammasome activation in pulmonary vessels has been considered a critical factor for pulmonary arterial remodelling [3], there are no specific therapeutic targets.

Pyroptosis is a form of inflammatory cell death different from apoptosis, necrosis, ferroptosis, and autophagic cell death, characterized by the activation of the inflammasome and the caspase family and the release of numerous proinflammatory cytokines [4]. Pyroptosis is broadly classified into classical caspase-1-dependent cell pyroptosis and nonclassical caspase-4/5/11-dependent cell pyroptosis. Inflammasome complexes, caspase1, the gasdermin family, interleukin- 18 (IL-18) and IL-1β are pivotal components of caspase-1-dependent pyroptosis [5]. Activated inflammasomes, through such components as such as nucleotide-binding domains and leucine-rich repeat receptors, recruit apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC) to assemble into inflammasome complexes to engage caspase-1 activation [6]. Among the various inflammasome complexes, the nucleotide-binding oligomerization domain-like protein 3 (NLRP3)/ASC complex is the most well characterized [7]. The NLRP3/ASC complex activates caspase-1 to the CI. The caspase-1 fragment causes cleavage of the gasdermin D (GSDMD), pro-IL-18 and pro-IL-1β, leading to the formation of cell membrane pores and the release of IL-1β and IL-18 [8]. Pyroptosis is involved in the development and progression of PH. HPASMC pyroptosis contributes to PH [9,10,11]. Inhibition of the NLRP3 pathway attenuates LPS-induced acute heart failure in monocrotaline-induced PH rats [12]. The absence of ASC has a protective effect in hypoxic PH [13, 14]. Knockout of caspase-1 attenuates the pathogenic features of PH, such as pulmonary arterial remodelling, right heart dysfunction, and pulmonary vascular fibrosis [15]. IL-1β and IL-18 also drive the apoptosis resistance and overproliferation of HPASMCs through several different mechanisms [15,16,17,18]. These results indicate that pyroptosis plays a significant role in the occurrence and progression of PH.

Disulfiram (DSF), an FDA-approved drug for alcohol addiction, has recently been shown to block pyroptosis and cytokine release in cells by inhibiting the binding of N-GSDMD to acidic phospholipids in the inner leaflet of the cell plasma membrane [19]. Though existing treatments for PH have significantly improved the outcomes of patients with PH [20], many patients do not meet the expectations. In this study, we investigated whether DSF could alleviate right ventricular systolic pressure (RVSP), right ventricular hypertrophy (RVH) and vascular remodelling in rodent models of hypoxia-induced PH by inhibiting the pyroptosis of HPASMCs, providing a novel therapeutic option for the treatment of PH.

Materials and methods

Measurements of plasma IL-1β and IL-18 in PH patients

The blood samples used in this study were obtained from inpatients who underwent right heart catheterization in Wuhan Sixth Hospital from 2020 to 2022 (Additional file 1: Table S1). Fourteen patients with idiopathic, hereditary, pulmonary disease-associated and left heart-associated PH and 16 patients without PH were selected for this study. Pulmonary artery pressure was measured in all patients by right heart catheterization. The diagnostic criterion for PH was a mean pulmonary artery pressure at rest (mPAP) ≥ 25 mmHg measured by right heart catheter [2].

Cell culture

HPASMCs were obtained from iCell Bioscience (Shanghai, China). Cells were cultured in Dulbecco’s modified Eagle medium (DMEM) (Keygen, China) supplemented with 10% foetal bovine serum (ProCell, China) and smooth muscle cell growth supplement (#1052, ScienCell) at 37 °C in a 5% CO2 incubator. Hypoxia was induced by growth in a hypoxic incubator at 2% O2.

Animals and treatments

Male animals were selected in this study to avoid hormonal effects. Animals were marked with a numerical code to ensure that they were randomly assigned to a different group, as follows: (a) normoxia for 28 days followed by vehicle (corn oil), (b) normoxia for 28 days followed by DSF (HY-B0240, MCE, Shanghai, China), (c) hypoxia for 28 days followed by vehicle (corn oil), and (d) hypoxia for 28 days followed by DSF. In the hypoxia group, male C57 mice and Sprague–Dawley rats were continuously exposed to hypoxia (10% O2) in a normobaric hypoxic chamber for 4 weeks. The hypoxic environment was achieved by supplementing with 100% nitrogen and was checked with an oxygen meter (CY-12C, Hangzhou, China) to detect the oxygen concentration. The normoxia group was in the same room but with 21% O2. Then each control group received vehicle (corn oil) and the each DSF group received DSF through intragastric administration at a dose of 50 mg/kg/day after 28 days of hypoxia.

Haemodynamic analysis and ventricular weight measurement

After the mice were anaesthetized, they were intubated and ventilated with a small animal ventilator (DW3000-B, Huaibei Zhenghua Biological Instrument Equipment Co., Ltd., Anhui, China) with a tidal volume of 1 ml and a respiratory frequency of 100 breaths/min using room air. RVSP proceeded immediately after opening the chest. Specifically, a needle with 0.45 mm in diameter and 16 mm in length was carefully inserted into the apex of the right ventricle.

After the rats were anaesthetized, the right jugular vein was exposed, and a PE-50 curved catheter was inserted into the right jugular vein to record the mean pulmonary artery pressure (mPAP). All animals were anaesthetized by intraperitoneal injection of sodium pentobarbital (30 mg/kg). The RVSP and mPAP were recorded using a PowerLab data acquisition system (AD instrument) and averaged over at least 10 consecutive heartbeats.

At the end of the haemodynamic measurements, the venous blood, heart and lavaged lungs were collected from the animals. The blood was centrifuged at 2500 rpm for 10 min, and the plasma was collected and stored at − 80 °C. The heart was taken to measure the right ventricular hypertrophy index, also referred to as the Fulton index [(the weight ratio of the wall of the right ventricle to the left ventricle plus septum: RV/(LV + S)]. The right lung was frozen in liquid nitrogen, stored at − 80 °C and used for subsequent western blot (WB) experiments. The left lung was fixed with 4% paraformaldehyde at room temperature (r.t.) for subsequent paraffin embedding.

Histological analysis

Fixed left lungs were sectioned at the largest cross-section (5 μm) and subjected to haematoxylin and eosin (HE) staining. Histological snapshots were taken under a microscope (Olympus, Tokyo, Japan). Distal pulmonary arteries with a diameter of 50–100 μm were selected for taking histological snapshots under a microscope (Olympus, Tokyo, Japan). The extent of pulmonary artery remodelling was quantified by calculating the ratio of the inner wall area to the maximum area of the vessel.

Immunofluorescence staining

The paraffin-embedded lung tissue sections were baked at 65 °C for 45 min and deparaffinized. Antigen repair was conducted using the microwave thermal repair method. BSA (10%) was used to block nonspecific antigens for 45 min at r.t. The sections were then incubated overnight at 4 °C with the following primary antibodies: α-SMA (1:100, Proteintech). Next, the sections were incubated with the secondary antibody corresponding to the primary antibody for 1 h at 37 °C. Finally, the nucleus was counterstained with DAPI for 10 min. The sections were sealed with anti-fluorescence quencher and stored at 4 °C in the dark. Fluorescence microscopy was performed on an Olympus fluorescence microscope. The fluorescence intensity was quantified using ImageJ software.

Western blot analysis

Total protein was extracted from lung tissues and cells into RIPA buffer through ultrasonic lysis, and then the total protein concentration was measured using a BCA assay kit (Beyotime, Shanghai, China). Standard 10% or 12.5% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate proteins of different molecular weights. The proteins were electrotransferred to polyvinylidene difluoride (PVDF; Millipore, USA) membranes by electrophoresis. The membranes were blocked with Tris-buffered saline with Tween 20 (TBST) containing 5% nonfat skimmed milk at r.t. for 1 h. The primary antibody was incubated at 4 °C, and the secondary antibody was incubated at r.t. The blots were visualized with chemiluminescent reagents (Proteintech, China). Semiquantitative analysis was conducted with ImageJ software. The following primary antibodies were used: total and cleaved N-terminal GSDMD antibody (TA4012), NLRP3 antibody (T55651), IL1 beta antibody (TA5103) were purchased from Abmart (Shanghai, China). GSDMD Full Length + N-terminal (A10164), caspase-1 (A16792), ASC (A1170), IL18 (A20473) antibodies were purchased from ABclonal (Wuhan, China).

ELISA

ELISA kits for mouse IL-1β (RK00006), human IL-1β (RK00001), rat IL-1β (RK00009) and human IL-18 (RK00176) were obtained from ABclonal (Wuhan, China), and mouse IL-18 (EK0433) and rat IL-18 (EK0592) were obtained from BOSTER (Wuhan, China). ELISA was performed according to the manufacturer’s instructions.

Hoechst 33,342 and propidium iodide (PI) fluorescence staining

Cell death was assessed by Hoechst 33,342 and PI fluorescence staining according to the manufacturer’s instructions (c1056, Beyotime, China). Briefly, HPASMCs were seeded in 6-well plates and treated with DSF (10 μmol/L) for 24 h with or without hypoxia (2% O2). The cell culture supernatant was removed, and cell staining buffer containing 5 μL each of Hoechst 33,342 and PI was added. Then the cells were incubated for 25 min at 4 °C in the dark. Stained cells were checked under an inverted fluorescence microscope (OLYMPUS IX71). The percentage of PI-positive cells in each field was recorded and analysed using ImageJ software.

Lactate dehydrogenase release assay

LDH release was detected with a lactate dehydrogenase cytotoxicity assay kit (C0017, Beyotime, China). Briefly, HPASMCs were cultured in 96-well plates until the cells proliferated to approximately 60% confluence and then were treated with DSF (10 μmol/L) for 24 h with or without hypoxia. The cell culture supernatant (120 μL) was collected and mixed with 60 μL of substrate and then incubated for 30 min at r.t. The OD490 was measured with a full-wavelength microplate reader (Thermo Fisher).

Statistical analysis

For animal experiments, “N” represents the number of animals in which the same treatment was performed; for cell experiments, “N” represents the number of independent experiments performed with primary cells from different individuals or cells at different passages. All data are expressed as the mean ± SEM. The data were analysed for statistical significance with IBM SPSS Statistics software (version 23). Graphs were generated with GraphPad Prism 8.0 (GraphPad Software, USA). The differences were analysed using Student’s t test or one-way ANOVA followed by Bonferroni’s multiple comparison test when the data followed a Gaussian distribution. Nonparametric tests (Kruskal–Wallis test) were carried out when data were not normally distributed. The experiments followed the principle of randomization, and the data analysis was performed in a blinded manner whenever possible. P < 0.05 was considered statistically significant.

Results

Lung tissue pyroptosis-related gene expression and plasma IL-1β and IL-18 concentration in patients with PH increase

We downloaded and re-analysed public databases GSE113439 and GSE15197 [21, 22] and observed that the expression levels of NLRP3, ASC (PYCARD), IL18, CASP1 and GSDMD were higher in patients with PH than normal controls (Fig. 1A and B). GSE113439 and GSE15197 were merged after removing batch effects [23]. We integrated GSE113439 and GSE15197, and unified modal approximation and projection (UMAP) analysis and expression density plots revealed the spread of the respective datasets before and after the removal of batch effects (Fig. 1C–F) [23]. We then normalized the expression profiles of these 57 samples (Fig. 1G). Gene set enrichment analysis (GSEA) of pyroptosis-related genes was performed on the integrated dataset (Fig. 1H). The genes related to pyroptosis were searched in the PubMed database (https://pubmed.ncbi.nlm.nih.gov/) and the Gene Ontology Resource (http://geneontology.org/). Finally, 67 genes were collected (Additional file 1: Table S2) [24, 25]. In addition, we observed that the levels of IL-18 and IL-1β were significantly higher in PH patients than in the control group (Fig. 1I and J).

Fig. 1
figure 1

Patients with pulmonary hypertension (PH) have high expression levels of canonical caspase-1-dependent pyroptosis genes. A The gene expression levels of NLRP3, IL18 and CASP1 in the lung tissue of patients with PH (n = 15) and control subjects (n = 11). The database is GSE113439. B The gene expression levels of ASC and GSDMD in the lung tissue of patients with PH (n = 18) and control subjects (n = 13). The database is GSE15197. C An unnormalized UMAP plot of GSE113439 and GSE15197. D A normalized UMAP plot of the GSE113439 and GSE15197. E An unnormalized expression density plot of GSE113439 and GSE15197. F A normalization expression density plot for GSE113439 and GSE15197. G Normalized expression distribution plots for GSE113439 and GSE15197. H GSEA of the pyroptosis gene set. Normalized enrichment score (NES) = 1.5578, nominal P value = 0.0301. I Plasma IL-1β levels in patients with PH increase. J Plasma IL-18 levels in patients with PH increase. Values are the mean ± S.E.M. and were analysed by the unpaired two-tailed Student’s t test. *P < 0.05 vs. the normal control

Full size image

DSF attenuates the progression of pulmonary hypertension in mice

To evaluate whether DSF elicits its action in the progression of PH, we assessed the pulmonary and right heart haemodynamic parameters as well as lung histological changes in hypoxia-induced PH mice after DSF treatment (Fig. 2A). DSF significantly attenuated PH by reducing RVSP to 82.0% (vehicle, 29.01 ± 0.35 mmHg versus DSF, 23.79 ± 0.80 mmHg; Fig. 2B) and RV/(LV + S) to 78.8% (vehicle, 0.33 ± 0.007 versus DSF, 0.26 ± 0.004; Fig. 2C). Histopathological analysis revealed that DSF treatment moderately inhibited hypoxia-induced pulmonary vascular remodelling, manifested by a reduction in medial wall thickness (%): medial area/cross-sectional area (CSA) (Fig. 2D and E).

Fig. 2
figure 2

DSF attenuates the development of hypoxia-induced PH in mice. A Experimental design timeline of DSF therapy in hypoxia-induced PH in mice. B, C RVSP and RV/(LV + S) of mice that were treated with DSF after 4 weeks hypoxia (n = 6 each). D HE-stained images and immunofluorescence images of α-smooth muscle actin (green) expression in the pulmonary arteries from mice subjected to hypoxia and therapy with DSF. Scale bar: 50 μm, (n = 6 each). E Statistical annalysis of the ratio of medial area/CSA (pulmonary arteries with diameter 50–100 μm) for mice exposed to hypoxia and given DSF (n = 6 each). Values are the mean ± SEM. Statistical significance was analysed by one-way ANOVA test followed by Bonferroni’s multiple comparison test or the Kruskal–Wallis test. *P < 0.05 vs. vehicle, and #P < 0.05 vs. normoxia (n = 5 each). i.g.: intragastric

Full size image

DSF attenuates the progression of pulmonary hypertension in rats

To evaluate the therapeutic effect of DSF in hypoixa-treated rats, oral DSF (50 mg/kg) was applied to rats after 4 weeks of hypoxia once a day (Fig. 3A). HE staining and α-SMA immunofluorescence staining showed increased artery wall thickness and a narrowed vascular lumen after 28 days of hypoxia in rats, and treatment with DSF partially reversed this vascular remodelling. Specifically, DSF markedly attenuated the increase in RVSP (DSF, 27.95 ± 1.74 mmHg versus vehicle, 35.65 ± 1.43 mmHg; P ≤ 0.001; Fig. 3B) and medial area/CSA (%) (Fig. 3D and E) in hypoxia-treated rats. In addition, rats with hypoxia-induced PH treated with DSF exhibited improvements in right heart failure, such as in a lower RV/(LV + S) (DSF, 0.34 ± 0.01 versus vehicle, 0.41 ± 0.01; P ≤ 0.001; Fig. 3C). These results indicate a reduction in the severity of PH in rats treated with DSF.

Fig. 3
figure 3

DSF attenuates the development of hypoxia-induced PH in rats. A Timeline of DSF therapy in hypoxia-induced PH in rats (n = 5 each). B, C RVSP and RV/(LV + S) of rats that were treated with DSF after 4 weeks of hypoxia (n = 5 each). D Representative HE lung sections and immunofluorescence images of α-SMA (green) in rats exposed to hypoxia and treated with DSF. Scale bar: 50 μm (n = 5 each). E Quantification of the medial area/CSA in hypoxia-treated rats treated with DSF (n = 5 each). Values are the mean ± SEM. Statistical significance was analysed by one-way ANOVA followed by Bonferroni’s multiple comparison test or the Kruskal–Wallis test. *P < 0.05 vs. vehicle, and #P < 0.05 vs. normoxia (n = 5 each)

Full size image

DSF inhibits the formation of N-GSDMD and the release of IL-18 and IL-1β in the lung tissue of hypoxia-induced PH in mice and rats

The accumulation of N-GSDMD on the cell membrane and the formation of membrane pores promote membrane rupture that causes IL-1β and IL-18 release, which are characteristic of cell pyroptosis. Pyroptosis plays a role in the development of PH, and DSF was recently found to inhibit pyroptosis [19]. We detected the expression of canonical pyroptosis pathway-related proteins in hypoxia-treated mouse lung tissue by WB. The results showed that the expression of NLRP3, ASC, caspase1 and GSDMD in the hypoxia group was higher than that in the normoxia group (Figs. 4A–C, 5A–E). Although the expression of NLRP3, ASC, caspase1 and GSDMD showed no significant changes in the lung tissue of mice and rats exposed to hypoxia with DSF treatment, the expression of N-GSDMD was reduced. These results indicated that DSF treatment after hypoxia had no inhibitory effect on the changes in NLRP3, ASC, caspase1 and GSDMD. Furthermore, inhibiting pyroptosis reduced the release of inflammatory cytokines. Therefore, we used ELISA to detect the expression of IL-18 and IL-1β and found that the IL-18 and IL-1β concentrations in the plasma of hypoxia-treated mice and rats were significantly reduced after DSF treatment (Figs. 4D, E, 5F, G).

Fig. 4
figure 4

DSF inhibits the formation of N-GSDMD and the release of IL-18 and IL-1β in the lung tissue of PH mice. A Representative WB images and analysis of caspase-1 and CI. caspase-1 and IL-1β (n = 5 each). B Representative WB images and analysis of GSDMD, N-GSDMD and IL-18 (n = 5 each). C Representative WB images and analysis of NLRP3 and ASC. D, E ELISA detection of inflammatory factors (IL-18 and IL-1β) in the plasma, (n = 6 each). Values are the mean ± SEM. Statistical significance was analysed by one-way ANOVA followed by Bonferroni’s multiple comparison test or the Kruskal–Wallis test. *P < 0.05 vs. vehicle, and #P < 0.05 vs. normoxia

Full size image
Fig. 5
figure 5

DSF inhibits the formation of N-GSDMD and the release of IL-18 and IL-1β in the lung tissue of hypoxia-induced PH rats. A Representative WB images and analysis of caspase-1 and CI. caspase-1. B Representative WB images and analysis of IL-18. C Representative WB images and analysis of IL-1β. D Representative WB images and analysis of GSDMD and N-GSDMD. E Representative WB images and analysis of NLRP3 and ASC. F, G ELISA detection of inflammatory factors (IL-18 and IL-1β). Values are the mean ± SEM. Statistical significance was analysed by one-way ANOVA followed by Bonferroni’s multiple comparison test or the Kruskal–Wallis test. *P < 0.05 vs. vehicle, and #P < 0.05 vs. normoxia (n = 5 each)

Full size image

DSF inhibits pyroptosis of HPASMCs under hypoxic conditions

Inflammatory changes and immune dysregulation influence the development and progression of PH, in which cell pyroptosis plays an important role. First, the changes in pyroptosis of HPASMCs under hypoxic conditions after DSF treatment were observed. The results showed that DSF reversed hypoxia-induced pyroptosis (Fig. 6A and B). Furthermore, we continued to explore the expression of pyroptosis-related proteins in HPASMCs under hypoxic conditions after DSF treatment. The results demonstrated that DSF did not change the upregulation of NLRP3, ASC, CI.caspase1, caspase1, IL-1β, IL-18 and GSDMD were induced by hypoxia in vivo (Fig. 6B–G). However, it effectively inhibited the production of N-GSDMD, which reduced plasma membrane pore formation and cell pyroptosis (Fig. 6D). Similarly, cell culture supernatants were assayed for IL-1β and IL-18 concentrations by ELISA. The release of IL-1β and IL-18 was reduced as well (Fig. 6H and I).

Fig. 6
figure 6

DSF inhibits pyroptosis of HPASMCs under hypoxic conditions. A PI staining of pyroptotic HPASMCs under hypoxic conditions was significantly reduced after DSF treatment (10 μmol/L). Red: propidium iodide (PI); Blue: Hoechst 33,342. Scale bars = 100 µm (n = 5). B DSF reduced the release of LDH in HPASMCs subjected to hypoxia for 24 h (n = 4). C Representative WB images and analysis of caspase-1 and CI. caspase-1 (n = 3). D Representative WB images and analysis of GSDMD and N-GSDMD (n = 3). E Representative WB images and analysis of NLRP3 and ASC (n = 3). F, G Representative WB images and analysis of IL-18 and IL-1β (n = 3). H, I ELISA detection of the inflammatory factors IL-1β and IL-18. Values are the mean ± SEM. Statistical significance was analysed by one-way ANOVA followed by Bonferroni’s multiple comparison test or the Kruskal–Wallis test. *P < 0.05 vs. vehicle, and #P < 0.05 vs. normoxia

Full size image

Discussion

The primary findings of this study are as follows: (a) The expression levels of lung tissue pyroptosis pathway-related genes were increased in patients with PH. (b) Plasma IL-1β and IL-18 levels in patients with PH increased. (c) DSF attenuated the development of hypoxia-induced PH in mice and rats. (d) DSF inhibited the formation of N-GSDMD and the release of IL-18 and IL-1β in the lung tissue of hypoxic mice and rats. (e) DSF inhibited HPASMC pyroptosis under hypoxic conditions. In the in vivo experiments, DSF partially reversed the progression of experimental PH, as evidenced mainly by the decreases in RVSP, mPAP, and the degree of right ventricular hypertrophy. In the in vitro experiments, DSF inhibited the cell membrane perforation and lytic death in HPASMCs.

Hypoxia is one of the most common stimuli that induce cellular pyroptosis. The combination of hypoxia and pyroptosis is involved in various diseases, such as brain injury [26, 27], cancer [28], and myocardial ischaemia/reperfusion [29, 30]. The first step in pyroptosis involves inflammasome assembly and activation. The intimate link between hypoxia and NLRP3 inflammation has been well described [31,32,33,34]. Hypoxia/reoxygenation activates NLRP3 inflammasome-mediated pyroptosis by upregulating reactive oxygen species (ROS) production [35]. Hypoxia-induced ROS contribute to myoblast pyroptosis in obstructive sleep apnoea via the NF-κB/hypoxia-inducible factor 1α (HIF-1α) signalling pathway [36]. HIF-1α may regulate inflammatory responses through the NLRP3 inflammasome complex [37, 38]. ROS and HIF-1α are involved in the development and progression of PH as the initial cellular response to hypoxic stimuli.

Both preclinical and clinical studies support the role of inflammasomes in the progression of PH [13, 39,40,41]. Acute and chronic inflammation responses characterize the vascular remodelling processes in PH. The initiation of inflammatory cascade plays a key role in pyroptosis and its follow-up reaction [42]. Further, most research on inflammasome activation has focused on specialized immune cells. A growing number of studies reveal that cell pyroptosis occurs in multiple cell types, including vascular smooth muscle cells (VSMCs), neutrophils, epithelial cells, dendritic cells, macrophages, endothelial cells, and cardiomyocytes [25, 43,44,45,46,47]. First, IL-1β receptor and IL-18 receptor are expressed at high levels on fibroblasts and VSMCs [48,49,50]. IL-18 and IL-1β expressed by VSMCs play important roles in cardiovascular disease [51,52,53,54]. Moreover, VSMCs can induce monocytes to express IL-1β and IL-18, which in turn promote the proliferation and migration of VSMCs [55, 56]. As mentioned earlier, both IL-18 and IL-1β can promote the proliferation and hypertrophy of HPASMCs, leading to pulmonary artery remodelling. Furthermore, inhibition of NLRP3/caspase-1/IL-1β signalling pathway can alleviate diabetic vascular remodelling [57]. GSDMD, an executor of pyroptosis, is strongly increased in patients with primary PH and in rodent PH models [58,59,60,61].

DSF, an FDA-approved drug for the treatment of alcohol addiction, has recently been repurposed as a drug for the treatment of cancer and other diseases. DSF is involved in various stress-response pathways in cells, such as antibacterial, anti-inflammatory, anti-obesity and anticancer pathways. More specifically, DSF has been leveraged to treat cancer by upregulating ROS, DNA damage, and enzymatic inhibition to inhibit the proliferation of cancer cells [62]. DSF inhibits the viability of hepatocellular carcinoma cells by disabling the HIF-mediated hypoxia signalling pathway [63]. It also inhibits N-GSDMD plasma membrane pore formation and inhibits the formation of neutrophil extracellular traps [19, 64]. These findings suggest the potential value of DSF after 60 years of research.

Pulmonary vascular remodelling is an important manifestation of the development and progression of PH, as evidenced by the hypertrophy and hyperproliferation of HPASMCs. IL-18 and IL-1β act as bridges to tightly link pyroptosis and pulmonary vascular remodelling. As described above, both IL-18 and IL-1β have a role in promoting the proliferation and hypertrophy of HPASMCs. This suggests that DSF inhibits PASMC proliferation and hypertrophy by reducing pyroptosis, which ultimately slows the process of pulmonary artery remodelling.

Conclusion and perspectives

In this study, we found that the DSF-triggered reduction in pyroptosis in the lungs was mainly derived from reduced N-GSDMD production in HPASMCs in hypoxia-exposed mice and rats rather than from the NLRP3-ASC-caspase1-GSDMD pathway. The reduced release of IL-18 and IL-1β following DSF treatment is consistent with the downregulation of pyroptosis. This suggests that DSF exerts beneficial effects on PH by inducing reduced N-GSDMD production in HPASMCs. There is an unmet demand for therapeutic approaches concentrating on pulmonary vascular remodelling in the clinic. Our results suggest that DSF may become a therapeutic option for PH patients.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

PH:

Pulmonary hypertension

DSF:

Disulfiram

GSDMD:

Gasdermin D

N-GSDMD:

N-terminal domain of GSDMD

Cl.Caspase:

Cleaved-caspase

RVSP:

Right ventricular systolic pressure

mPAP:

Mean pulmonary artery pressure

RVH:

Right ventricular hypertrophy

HPASMCs:

Human pulmonary artery smooth muscle cells

IL:

Interleukin

NLRP3:

Nucleotide-binding oligomerization domain-like protein3

ASC:

Apoptosis-associated speck-like protein containing a caspase-recruitment domain

LDH:

Lactate dehydrogenase

GSEA:

Gene set enrichment analysis

NES:

Normalized enrichment score

ELISA:

Enzyme-linked immunosorbent assay

WB:

Western blot

VSMCs:

Vascular smooth muscle cells

References

  1. Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS, Schermuly RT, Stenmark KR, Rabinovitch M. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019;53:1801887.

    Article  CAS  Google Scholar 

  2. Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA. 2022;327:1379–91.

    Article  CAS  Google Scholar 

  3. Scott TE, Kemp-Harper BK, Hobbs AJ. Inflammasomes: a novel therapeutic target in pulmonary hypertension? Br J Pharmacol. 2019;176:1880–96.

    Article  CAS  Google Scholar 

  4. Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther. 2021;6:128.

    Article  Google Scholar 

  5. Burdette BE, Esparza AN, Zhu H, Wang S. Gasdermin D in pyroptosis. Acta Pharmaceutica Sinica B. 2021;11:2768–82.

    Article  CAS  Google Scholar 

  6. Man SM, Kanneganti T-D. Regulation of inflammasome activation. Immunol Rev. 2015;265:6.

    Article  CAS  Google Scholar 

  7. Segovia JA, Tsai S-Y, Chang T-H, Shil NK, Weintraub ST, Short JD, Bose S. Nedd8 regulates inflammasome-dependent caspase-1 activation. Mol Cell Biol. 2015;35:582–97.

    Article  Google Scholar 

  8. Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, Zhuang Y, Cai T, Wang F, Shao F. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526:660–5.

    Article  CAS  Google Scholar 

  9. Zhang M, Xin W, Yu Y, Yang X, Ma C, Zhang H, Liu Y, Zhao X, Guan X, Wang X, Zhu D. Programmed death-ligand 1 triggers PASMCs pyroptosis and pulmonary vascular fibrosis in pulmonary hypertension. J Mol Cell Cardiol. 2020;138:23–33.

    Article  CAS  Google Scholar 

  10. He S, Ma C, Zhang L, Bai J, Wang X, Zheng X, Zhang J, Xin W, Li Y, Jiang Y, et al. GLI1-mediated pulmonary artery smooth muscle cell pyroptosis contributes to hypoxia-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2020;318:L472–82.

    Article  CAS  Google Scholar 

  11. Li Y, Zhang J, Sun H, Yu X, Chen Y, Ma C, Zheng X, Zhang L, Zhao X, Jiang Y, et al. RPS4XL encoded by lnc-Rps4l inhibits hypoxia-induced pyroptosis by binding HSC70 glycosylation site. Mol Therapy Nucleic Acids. 2022;28:920–34.

    Article  CAS  Google Scholar 

  12. Guo L, Qin G, Cao Y, Yang Y, Dai S, Wang L, Wang E. Regulation of the immune microenvironment by an NLRP3 inhibitor contributes to attenuation of acute right ventricular failure in rats with pulmonary arterial hypertension. J Inflamm Res. 2021;14:5699–711.

    Article  CAS  Google Scholar 

  13. Cero FT, Hillestad V, Sjaastad I, Yndestad A, Aukrust P, Ranheim T, Lunde IG, Olsen MB, Lien E, Zhang L, et al. Absence of the inflammasome adaptor ASC reduces hypoxia-induced pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2015;309:L378–87.

    Article  CAS  Google Scholar 

  14. Li Y, Li Y, Li L, Yin M, Wang J, Li X. PKR deficiency alleviates pulmonary hypertension via inducing inflammasome adaptor ASC inactivation. Pulm Circ. 2021;11:20458940211046156.

    Article  Google Scholar 

  15. Udjus C, Cero FT, Halvorsen B, Behmen D, Carlson CR, Bendiksen BA, Espe EKS, Sjaastad I, Løberg EM, Yndestad A, et al. Caspase-1 induces smooth muscle cell growth in hypoxia-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2019;316:L999.

    Article  CAS  Google Scholar 

  16. Rong W, Liu C, Li X, Wan N, Wei L, Zhu W, Bai P, Li M, Ou Y, Li F, et al. Caspase-8 promotes pulmonary hypertension by activating macrophage-associated inflammation and IL-1β (Interleukin 1β) production. Arterioscler Thromb Vasc Biol. 2022;42:613–31.

    Article  CAS  Google Scholar 

  17. Fu C, Hao S, Liu Z, Xie L, Wu X, Wu X, Li S. SOD2 ameliorates pulmonary hypertension in a murine model of sleep apnea via suppressing expression of NLRP3 in CD11b cells. Respir Res. 2020;21:9.

    Article  CAS  Google Scholar 

  18. Parpaleix A, Amsellem V, Houssaini A, Abid S, Breau M, Marcos E, Sawaki D, Delcroix M, Quarck R, Maillard A, et al. Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension. Eur Respir J. 2016;48:470–83.

    Article  CAS  Google Scholar 

  19. Hu JJ, Liu X, Xia S, Zhang Z, Zhang Y, Zhao J, Ruan J, Luo X, Lou X, Bai Y, et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol. 2020;21:736–45.

    Article  CAS  Google Scholar 

  20. Mandras SA, Mehta HS, Vaidya A. Pulmonary hypertension: a brief guide for clinicians. Mayo Clin Proc. 2020;95:1978–88.

    Article  CAS  Google Scholar 

  21. Mura M, Cecchini MJ, Joseph M, Granton JT. Osteopontin lung gene expression is a marker of disease severity in pulmonary arterial hypertension. Respirology (Carlton, Vic). 2019;24:1104–10.

    Article  Google Scholar 

  22. Rajkumar R, Konishi K, Richards TJ, Ishizawar DC, Wiechert AC, Kaminski N, Ahmad F. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2010;298:H1235–48.

    Article  CAS  Google Scholar 

  23. Shen W, Song Z, Zhong X, Huang M, Shen D, Gao P, Qian X, Wang M, He X, Wang T, et al. Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform. iMeta. 2022;1:e36.

    Article  Google Scholar 

  24. Wang N, Ding L, Liu D, Zhang Q, Zheng G, Xia X, Xiong S. Molecular investigation of candidate genes for pyroptosis-induced inflammation in diabetic retinopathy. Front Endocrinol. 2022;13: 918605.

    Article  Google Scholar 

  25. Jia C, Chen H, Zhang J, Zhou K, Zhuge Y, Niu C, Qiu J, Rong X, Shi Z, Xiao J, et al. Role of pyroptosis in cardiovascular diseases. Int Immunopharmacol. 2019;67:311–8.

    Article  CAS  Google Scholar 

  26. Kang YW, Kim YS, Park JY, Chu G-E, Yang YC, Choi BY, Cho WG. Hypoxia-induced apoptosis of astrocytes is mediated by reduction of Dicer and activation of caspase-1. Cell Biol Int. 2020;44:1394–404.

    Article  CAS  Google Scholar 

  27. Jiang Z, Chen J, Chen J, Lei Z, Chen H, Wu J, Bai X, Wanyan P, Yu Q. Anti-inflammatory effects of paeoniflorin caused by regulation of the hif1a/miR-210/caspase1/GSDMD signaling pathway in astrocytes: a novel strategy for hypoxia-induced brain injury in rats. Immunopharmacol Immunotoxicol. 2021;43:410–8.

    Article  CAS  Google Scholar 

  28. Hou J, Zhao R, Xia W, Chang C-W, You Y, Hsu J-M, Nie L, Chen Y, Wang Y-C, Liu C, et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020;22:1264–75.

    Article  CAS  Google Scholar 

  29. Shi H, Gao Y, Dong Z, Je Y, Gao R, Li X, Zhang S, Ma L, Sun X, Wang Z, et al. GSDMD-mediated cardiomyocyte pyroptosis promotes myocardial I/R injury. Circ Res. 2021;129:383–96.

    Article  CAS  Google Scholar 

  30. Qiu Z, Lei S, Zhao B, Wu Y, Su W, Liu M, Meng Q, Zhou B, Leng Y, Xia Z-Y. NLRP3 inflammasome activation-mediated pyroptosis aggravates myocardial ischemia/reperfusion injury in diabetic rats. Oxid Med Cell Longev. 2017;2017:9743280.

    Article  Google Scholar 

  31. Watanabe S, Usui-Kawanishi F, Karasawa T, Kimura H, Kamata R, Komada T, Inoue Y, Mise N, Kasahara T, Takahashi M. Glucose regulates hypoxia-induced NLRP3 inflammasome activation in macrophages. J Cell Physiol. 2020;235:7554–66.

    Article  CAS  Google Scholar 

  32. Satish M, Agrawal DK. Atherothrombosis and the NLRP3 inflammasome—endogenous mechanisms of inhibition. Transl Res. 2020;215:75–85.

    Article  CAS  Google Scholar 

  33. Zhou Z, Wang Z, Guan Q, Qiu F, Li Y, Liu Z, Zhang H, Dong H, Zhang Z. PEDF inhibits the activation of NLRP3 inflammasome in hypoxia cardiomyocytes through PEDF receptor/phospholipase A2. Int J Mol Sci. 2016;17:2064.

    Article  Google Scholar 

  34. Xin X, Yang K, Liu H, Li Y. Hypobaric hypoxia triggers pyroptosis in the retina via NLRP3 inflammasome activation. Apoptosis. 2022;27:222–32.

    Article  CAS  Google Scholar 

  35. Qiu Z, He Y, Ming H, Lei S, Leng Y, Xia Z-Y. Lipopolysaccharide (LPS) aggravates high glucose- and hypoxia/reoxygenation-induced injury through activating ROS-dependent NLRP3 inflammasome-mediated pyroptosis in H9C2 cardiomyocytes. J Diabetes Res. 2019;2019:8151836.

    Article  Google Scholar 

  36. Yu L-M, Zhang W-H, Han X-X, Li Y-Y, Lu Y, Pan J, Mao J-Q, Zhu L-Y, Deng J-J, Huang W, Liu Y-H. Hypoxia-induced ROS contribute to myoblast pyroptosis during obstructive sleep apnea via the NF-B/HIF-1 signaling pathway. Oxid Med Cell Longev. 2019;2019:4596368.

    Article  Google Scholar 

  37. Jiang Q, Geng X, Warren J, Eugene Paul Cosky E, Kaura S, Stone C, Li F, Ding Y. Hypoxia inducible factor-1α (HIF-1α) mediates NLRP3 inflammasome-dependent-pyroptotic and apoptotic cell death following ischemic stroke. Neuroscience. 2020;448:126–39.

    Article  CAS  Google Scholar 

  38. Gupta N, Sahu A, Prabhakar A, Chatterjee T, Tyagi T, Kumari B, Khan N, Nair V, Bajaj N, Sharma M, Ashraf MZ. Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia. Proc Natl Acad Sci USA. 2017;114:4763–8.

    Article  CAS  Google Scholar 

  39. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, Trembath RC, Jennings S, Barker L, Nicklin P, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010;122:920–7.

    Article  CAS  Google Scholar 

  40. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, Tuder RM. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186:261–72.

    Article  Google Scholar 

  41. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res. 2009;104:236.

    Article  CAS  Google Scholar 

  42. Dutzmann J, Daniel J-M, Bauersachs J, Hilfiker-Kleiner D, Sedding DG. Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovasc Res. 2015;106:365–74.

    Article  CAS  Google Scholar 

  43. Wortmann M, Peters AS, Erhart P, Körfer D, Böckler D, Dihlmann S. Inflammasomes in the pathophysiology of aortic disease. Cells. 2021; 10.

  44. Lénárt N, Brough D, Dénes Á. Inflammasomes link vascular disease with neuroinflammation and brain disorders. J Cereb Blood Flow Metab. 2016;36:1668–85.

    Article  Google Scholar 

  45. He X, Fan X, Bai B, Lu N, Zhang S, Zhang L. Pyroptosis is a critical immune-inflammatory response involved in atherosclerosis. Pharmacol Res. 2021;165: 105447.

    Article  CAS  Google Scholar 

  46. Pang Q, Wang P, Pan Y, Dong X, Zhou T, Song X, Zhang A. Irisin protects against vascular calcification by activating autophagy and inhibiting NLRP3-mediated vascular smooth muscle cell pyroptosis in chronic kidney disease. Cell Death Dis. 2022;13:283.

    Article  CAS  Google Scholar 

  47. Burger F, Baptista D, Roth A, da Silva RF, Montecucco F, Mach F, Brandt KJ, Miteva K. NLRP3 inflammasome activation controls vascular smooth muscle cells phenotypic switch in atherosclerosis. Int J Mol Sci. 2021;23:340.

    Article  Google Scholar 

  48. Porritt RA, Zemmour D, Abe M, Lee Y, Narayanan M, Carvalho TT, Gomez AC, Martinon D, Santiskulvong C, Fishbein MC, et al. NLRP3 inflammasome mediates immune-stromal interactions in vasculitis. Circ Res. 2021;129:e183–200.

    Article  CAS  Google Scholar 

  49. Zhang K, Zhang Y, Feng W, Chen R, Chen J, Touyz RM, Wang J, Huang H. Interleukin-18 enhances vascular calcification and osteogenic differentiation of vascular smooth muscle cells through TRPM7 activation. Arterioscler Thromb Vasc Biol. 2017;37:1933–43.

    Article  CAS  Google Scholar 

  50. Sahar S, Dwarakanath RS, Reddy MA, Lanting L, Todorov I, Natarajan R. Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis. Circ Res. 2005;96:1064–71.

    Article  CAS  Google Scholar 

  51. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schönbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med. 2002;195:245–57.

    Article  CAS  Google Scholar 

  52. Lin Y-C, Chiang C-H, Chang L-T, Sun C-K, Leu S, Shao P-L, Hsieh M-C, Tsai T-H, Chua S, Chung S-Y, et al. Simvastatin attenuates the additive effects of TNF-α and IL-18 on the connexin 43 up-regulation and over-proliferation of cultured aortic smooth muscle cells. Cytokine. 2013;62:341–51.

    Article  CAS  Google Scholar 

  53. Westphal E, Herzberg M, Neumann I, Beibei L, Pilowski C, Li C, Werdan K, Loppnow H. Neutrophils process interleukin-1beta and interleukin-18 precursors in a caspase-1-like fashion–processing is inhibited by human vascular smooth muscle cells. Eur Cytokine Netw. 2006;17:19–28.

    CAS  Google Scholar 

  54. Kawamura A, Baitsch D, Telgmann R, Feuerborn R, Weissen-Plenz G, Hagedorn C, Saku K, Brand-Herrmann S-M, von Eckardstein A, Assmann G, Nofer J-R. Apolipoprotein E interrupts interleukin-1beta signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2007;27:1610–7.

    Article  CAS  Google Scholar 

  55. Li P, Li Y-l, Li Z-y, Wu Y-n, Zhang C-c, Xi A, Wang C-x, Shi H-t, Hui M-z, Xie B, et al. Cross talk between vascular smooth muscle cells and monocytes through interleukin-1β/interleukin-18 signaling promotes vein graft thickening. Arterioscler Thromb Vasc Biol. 2014;34:2001–11.

    Article  CAS  Google Scholar 

  56. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, Greene WC, Valente AJ. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem. 2006;281:15099–109.

    Article  CAS  Google Scholar 

  57. Fan Z, Yang J, Yang C, Zhang J, Cai W, Huang C. MicroRNA-24 attenuates diabetic vascular remodeling by suppressing the NLRP3/caspase-1/IL-1β signaling pathway. Int J Mol Med. 2020;45:1534–42.

    CAS  Google Scholar 

  58. Wu Y, Pan B, Zhang Z, Li X, Leng Y, Ji Y, Sun K, Chen AF. Caspase-4/11-mediated pulmonary artery endothelial cell pyroptosis contributes to pulmonary arterial hypertension. Hypertension (Dallas, Tex: 1979). 2022;79:536–48.

    Article  CAS  Google Scholar 

  59. Xing Y, Zhao J, Zhou M, Jing S, Zhao X, Mao P, Qian J, Huang C, Tian Z, Wang Q, et al. The LPS induced pyroptosis exacerbates BMPR2 signaling deficiency to potentiate SLE-PAH. FASEB J. 2021;35: e22044.

    Article  CAS  Google Scholar 

  60. Jarabicová I, Horváth C, Veľasová E, Bies Piváčková L, Vetešková J, Klimas J, Křenek P, Adameová A. Analysis of necroptosis and its association with pyroptosis in organ damage in experimental pulmonary arterial hypertension. J Cell Mol Med. 2022;26:2633–45.

    Article  Google Scholar 

  61. He W-t, Wan H, Hu L, Chen P, Wang X, Huang Z, Yang Z-H, Zhong C-Q, Han J. Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion. Cell Res. 2015;25:1285–98.

    Article  CAS  Google Scholar 

  62. Lu Y, Pan Q, Gao W, Pu Y, Luo K, He B, Gu Z. Leveraging disulfiram to treat cancer: mechanisms of action, delivery strategies, and treatment regimens. Biomaterials. 2022;281: 121335.

    Article  CAS  Google Scholar 

  63. Park H-j, Kim M-s, Cho K, Yun J-h, Choi Y-j, Cho C-h. Disulfiram deregulates HIF-α subunits and blunts tumor adaptation to hypoxia in hepatoma cells. Acta Pharmacol Sin. 2013;34:1208–16.

    Article  CAS  Google Scholar 

  64. Adrover JM, Carrau L, Daßler-Plenker J, Bram Y, Chandar V, Houghton S, Redmond D, Merrill JR, Shevik M, tenOever BR, et al. Disulfiram inhibits neutrophil extracellular trap formation and protects rodents from acute lung injury and SARS-CoV-2 infection. JCI Insight 2022; 7.

Download references

Acknowledgements

Not applicable.

Funding

This work was supported by National Natural Science Foundation of China (No. 81470252) to Tao Wang. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information

Author notes

  1. Shunlian Hu, Lu Wang and Yahan Xu have contributed equally to this work.

Authors and Affiliations

  1. Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China

    Shunlian Hu, Yahan Xu & Tao Wang

  2. The Center for Biomedical Research, National Health Committee (NHC) Key Laboratory of Respiratory Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China

    Shunlian Hu, Yahan Xu & Tao Wang

  3. Department of Respiratory and Critical Care Medicine, Miyun Teaching Hospital of Capital Medical University, Beijing, People’s Republic of China

    Lu Wang

  4. Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Miyun District, Beijing, People’s Republic of China

    Lu Wang

  5. Department of Respiratory and Critical Care Medicine, Beijing Miyun Hospital, Beijing, People’s Republic of China

    Lu Wang

  6. The Sixth Hospital of Wuhan City, Affiliated Hospital of Jianghan University, Beijing, People’s Republic of China

    Fajiu Li

Authors
  1. Shunlian Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yahan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fajiu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TW initiated the project and designed the experiments and revised the manuscript; SH and LW performed the molecular biological experiments, analysed the data and prepared the figures; SH and YX performed the animal experiments. SH wrote the paper. TW, SH, LW, FL approved the final version of the manuscript. All authors read and approved the final manuscript. #Shunlian Hu, Lu Wang and Yahan Xu have contributed equally to this work.

Corresponding author

Correspondence to Tao Wang.

Ethics declarations

Ethics approval and consent to participate

All animal care and experimental procedures were approved by the Animal Care and Use Committee of the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. All experiments involving animals were performed according to the recommendations in the ARRIS guidelines. The study was approved by the Ethics Committee of Tongji Hospital (IRB: TJ-IRB20210351). All recruited subjects signed written informed consent forms before their inclusion in the study, which conformed to the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Table S1. Clinical information of PAH subjects and controls in the study. Table S2. Gene set enrichment analysis details.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, S., Wang, L., Xu, Y. et al. Disulfiram attenuates hypoxia-induced pulmonary hypertension by inhibiting GSDMD cleavage and pyroptosis in HPASMCs. Respir Res 23, 353 (2022). https://doi.org/10.1186/s12931-022-02279-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12931-022-02279-0

Keywords

Respiratory Research

ISSN: 1465-993X

Contact us